Home » Stocks » BMY

Bristol-Myers Squibb Company (BMY)

Stock Price: $64.44 USD -0.02 (-0.03%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $64.40 -0.04 (-0.06%) May 7, 7:58 PM
Market Cap 144.42B
Revenue (ttm) 42.81B
Net Income (ttm) -6.22B
Shares Out 2.24B
EPS (ttm) -2.76
PE Ratio n/a
Forward PE 8.65
Dividend $1.88
Dividend Yield 2.92%
Trading Day May 7
Last Price $64.44
Previous Close $64.46
Change ($) -0.02
Change (%) -0.03%
Day's Open 64.70
Day's Range 64.19 - 65.39
Day's Volume 7,847,026
52-Week Range 52.43 - 66.93

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

FATE reports a wider Q1 loss on increased R&D expenses.

Other stocks mentioned: FATE, GILD, JNJ
1 day ago - Zacks Investment Research

NEW YORK, May 6, 2021 /PRNewswire/ -- DarwinHealth, a New York City-based biotechnology company, today announced a scientific research collaboration with Bristol-Myers Squibb Company (NYSE: BMY).  The r...

1 day ago - PRNewsWire

Quarter was awful, with no upside: Jim Cramer on Bristol Myers earnings

YouTube video

Jim Cramer and Stephanie Link, Hightower, react to Bristol Myers' disappointing earnings and the other names they're looking to instead.

2 days ago - CNBC Television

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference

3 days ago - Business Wire

Our constant need for medical products will be a major growth driver for these healthcare giants.

Other stocks mentioned: ABT
4 days ago - The Motley Fool

Going by historical performance, there is a 62% chance of a rise in BMY stock over the next month. Out of 116 instances in the last ten years that BMY stock saw a five-day decline of 5.2% or more, 72 of...

4 days ago - Forbes

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACC--BMS Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at upcoming ACC.21

4 days ago - Business Wire

Investors will have to wait for the full data set to see how much the drug could really help cancer patients.

5 days ago - The Motley Fool

Abecma is on the market.

Other stocks mentioned: BLUE
6 days ago - The Motley Fool

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--US FDA Accepts for Priority Review BMS's Application for Opdivo as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma

1 week ago - Business Wire

The big drugmaker reported disappointing first-quarter results.

1 week ago - The Motley Fool

Bristol-Myers Squibb Co (NYSE: BMY) joined other drugmakers in missing first-quarter earnings consensus due to a decline in medical visits and new diagnoses as COVID-19 cases surged at the start of the ...

1 week ago - Benzinga

Bristol-Myers (BMY) misses earnings and sales estimates in the first quarter on weak Opdivo sales.

1 week ago - Zacks Investment Research

Part of the problem was the company's strong performance a year ago.

1 week ago - The Motley Fool

Bristol Myers (BMY) delivered earnings and revenue surprises of -3.33% and -0.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Shares of Bristol-Myers Squibb (NYSE:BMY) decreased 1.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 1.16% year over year to $1.74, which misse...

1 week ago - Benzinga

Bristol Myers Squibb Co reported lower-than-expected first-quarter profit on Thursday as sales of its high margin cancer drugs Revlimid and Opdivo fell short of Wall Street estimates.

1 week ago - Reuters

High-quality pharmaceutical stocks comes with steady business, low valuations and solid dividend. Let's look at a handful of them now.

Other stocks mentioned: ABBV, AMGN, JNJ, MRNA, PFE, SFY
1 week ago - InvestorPlace

Some of the stocks that may grab investor focus today are: Wall Street expects Caterpillar Inc. (NYSE: CAT) to report quarterly earnings at $1.94 per share on revenue of $11.09 billion before the openin...

Other stocks mentioned: AAPL, AMZN, CAT, F, FB, MA, MCD
1 week ago - Benzinga

Bristol Myers (BMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

1 week ago - Zacks Investment Research

Let us take a look at what is in store for some of the pharma/biotech stocks, which are scheduled to report on Apr 29.

1 week ago - Zacks Investment Research

So, which pharmaceutical stocks should be on your radar, if dividends are a top priority? Consider these seven compelling opportunities.

Other stocks mentioned: ABBV, GILD, GSK, JNJ, NVS, MRK
1 week ago - InvestorPlace

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Take Part in the 7th Annual Truist Life Sciences Summit

1 week ago - Business Wire

With yields ranging from 2% to 10%, these income stocks can pad your pockets and generate serious long-term wealth.

Other stocks mentioned: IIPR, NEE, NLY, T
1 week ago - The Motley Fool

Other stocks mentioned: ABBV, AMGN, AZN, GILD, JNJ, MRK
1 week ago - GuruFocus

BMY vs. HZNP: Which Stock Is the Better Value Option?

1 week ago - Zacks Investment Research

NEW YORK--(BUSINESS WIRE)-- #BMY--INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Bristol-Myers Squibb Company's Directors and Officers for Breach of Fiduciary Duties–BMY

1 week ago - Business Wire

Eli Lilly and Co. (NYSE:LLY) jumped four places from last year to capture the top spot in IDEA Pharma's Pharmaceutical Innovation Index, supplanting the 2020 leader Roche (RHHBY). In the drug consulting...

Other stocks mentioned: LLY
1 week ago - GuruFocus

They're generating revenue now -- and more is on the way.

Other stocks mentioned: EXEL, VRTX
1 week ago - The Motley Fool

Not every stock is ridiculously expensive right now.

Other stocks mentioned: ABBV, TROX
2 weeks ago - The Motley Fool

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports first-quarter 2021 results.

2 weeks ago - Zacks Investment Research

European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Roche Holdings AG's (OTCMKTS: RHHBY) Enspryng, AbbVie Inc's (NYSE: AB...

Other stocks mentioned: ABBV, RHHBY
2 weeks ago - Benzinga

Bristol-Myers Squibb Co (NYSE: BMY) has announced new data from its two Phase 3 trials POETYK PSO-1 and POETYK PSO-2 for deucravacitinib, its oral, selective TYK2 inhibitor for moderate to severe plaque...

Other stocks mentioned: AMGN
2 weeks ago - Benzinga

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AADVMX2021--Bristol Myers Squibb Presents Positive Data at AAD

2 weeks ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AML--BMS Receives Positive CHMP Opinion for Onureg® (azacitidine tablets;CC-486) as Frontline Oral Maintenance Therapy forAdults w AML in First Remission

2 weeks ago - Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo + Yervoy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma

2 weeks ago - Business Wire

Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.

Other stocks mentioned: AMGN, REGN, REPL, RHHBY, SNY
2 weeks ago - GuruFocus

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

Is (BMY) Outperforming Other Medical Stocks This Year?

2 weeks ago - Zacks Investment Research

This undervalued pharmaceutical is a great buy in 2021.

2 weeks ago - The Motley Fool

Bristol-Myers Squibb Co (NYSE: BMY) continues to scale its CAR-T operations with the latest move to open its first cell manufacturing site in Europe and fifth worldwide. BMY is set to build a new cell t...

2 weeks ago - Benzinga

Bristol Myers Squibb (BMY) closed at $65.60 in the latest trading session, marking a +0.21% move from the prior day.

2 weeks ago - Zacks Investment Research

Bristol Myers (BMY) obtains FDA approval for Opdivo in combination with chemotherapy for patients with gastric cancer, among others.

2 weeks ago - Zacks Investment Research

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--US FDA Approves Opdivo in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer....

3 weeks ago - Business Wire

It's easy to build wealth on Wall Street when you own stakes in great businesses.

Other stocks mentioned: CRLBF, PLTR
3 weeks ago - The Motley Fool

The European Commission approves Bristol Myers' (BMY) Opdivo in combination with Cabometyx for first-line treatment of advanced renal cell carcinoma.

3 weeks ago - Zacks Investment Research

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Opdivo--BMS Receives EC Approval for Opdivo® (nivolumab) in Comb w Cabometyx® (cabozantinib) as First-Line Treatment for Patients w Advanced Renal Cell Carcin

3 weeks ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)-- #Dermatology--Pyramid Biosciences, Inc., a Boston-based, clinical-stage biotechnology company, today announced two new appointments to its leadership team.

3 weeks ago - Business Wire

See why the world's most acclaimed value investor is investing in these three stocks.

Other stocks mentioned: ABBV, MRK
3 weeks ago - The Motley Fool

Key recent clinical pipeline developments have prompted an analyst at Truist Securities to turn bullish on pharma giant Bristol-Myers Squibb Company (NYSE: BMY). The Bristol-Myers Squibb Analyst: Gregg ...

3 weeks ago - Benzinga

About BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and ps... [Read more...]

Industry
Drug Manufacturers-General
Founded
1887
CEO
Giovanni Caforio
Employees
30,250
Stock Exchange
NYSE
Ticker Symbol
BMY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 19 analysts, the average rating for BMY stock is "Buy." The 12-month stock price forecast is 75.44, which is an increase of 17.07% from the latest price.

Price Target
$75.44
(17.07% upside)
Analyst Consensus: Buy